Portada›Viernes 17 de octubre de 2025

Biomédicas del NASDAQ ante la SEC, viernes 17 de octubre de 2025

Los 34 documentos que 28 empresas del sector presentaron ante la SEC ese día, agrupados por tipo y con el enlace al original en EDGAR.

← jueves 16 de octubre de 2025 · lunes 20 de octubre de 2025 →

¿Lo quieres en tu correo cada mañana, y solo de tus empresas? Crear una cuenta.

Va en color lo que cambia el capital o avisa de un riesgo: las emisiones con precio (424B1, 424B2, 424B4 y 424B5), los 8-K con item 1.02, 1.03, 2.04, 3.01, 3.02 y 4.02, y cualquier documento en el que haya aparecido una frase vigilada, que va citada debajo. Lo demás va en tinta normal. Una cita marcada «por primera vez» es una frase que no estaba en el informe previo del mismo tipo de esa empresa. La etiqueta del formulario lleva a su explicación.

Emisiones y dilución

1. CLNNClene Inc.424B5Nueva emisión de acciones con precioEDGAR
2. GOVXGeoVax Labs, Inc.S-1Capacidad de emisión registradaEDGAR
   En el documentoDuda sustancial sobre la continuidad de la empresatexto original ▸

   …and may not remain in business. We have received a going concern opinion from our auditors. We have received a "going concern" opinion from our independent registered public accounting firm, reflecting substantial doubt about our ability to continue as a going concern. Our consolidated financial statements contemplate that we will continue as a going concern and do not contain any adjustments that might result if we were unable to continue as a going concern. Our ability…

   En el documentoAviso de incumplimiento de las reglas de cotizacióntexto original ▸

   …share price, and certain corporate governance requirements. There can be no assurances that we will be able to continue to comply with the applicable listing standards. On July 31, 2025, the “Company received a deficiency letter from the Listing Qualifications Department of the Nasdaq Stock Market (“Nasdaq”) notifying the Company that, for the preceding 30 consecutive business days, the closing bid price for the Company’s common…

   En el documentoPrograma de venta continua de acciones (ATM)texto original ▸

   …primarily from sales of our equity securities and from government grants and clinical trial assistance. During 2024, we closed four registered direct offerings of our Common Stock and warrants, as well as established the ATM Program (see footnote 6 to the consolidated financial statements included in this prospectus). Net proceeds to us from these offerings, after deducting commissions to the placement agent and sales agent, as applicable…
3. LXEOLexeo Therapeutics, Inc.424B5Nueva emisión de acciones con precioEDGAR
4. ONCYONCOLYTICS BIOTECH INC424B5Nueva emisión de acciones con precioEDGAR
   En el documentoDuda sustancial sobre la continuidad de la empresatexto original ▸

   …this prospectus supplement by reference to the Annual Report on Form 20-F have been so incorporated in reliance on the report (which contains an explanatory paragraph describing conditions that raise substantial doubt about the Company’s ability to continue as a going concern as described in Note 1 to the consolidated financial statements) of Ernst & Young LLP, an independent registered public accounting firm, given on the authority of said firm as experts in auditing and…

   En el documentoPrograma de venta continua de acciones (ATM)texto original ▸

   424B5 1 tm2528785d1_424b5.htm 424B5 Filed Pursuant to Rule 424(b)(5) Registration No. 333-289819 PROSPECTUS SUPPLEMENT (to Prospectus dated August 29, 2025) $50,000,000 Common Shares We have entered into an At-the-Market Sales Agreement (the “Sales Agreement”) with BTIG, LLC (the “Agent”) relating to our common shares offered by this prospectus supplement and the accompanying prospectus. In accordance with the terms of the Sales Agreement…
5. PTNPALATIN TECHNOLOGIES INCS-1/ACapacidad de emisión registrada (enmienda)EDGAR
   En el documentoDuda sustancial sobre la continuidad de la empresatexto original ▸

   …statements include, but are not limited to, statements about: ● our significant operating losses since our inception and our need to obtain additional financing has caused management to determine there is substantial doubt regarding our ability to continue as a going concern; ● our ability to obtain additional financing on terms acceptable to us, or at all, including unavailability of funds or delays in receiving funds as a result of economic disruptions; ● our expectation…

   En el documentoContrasplit de accionestexto original ▸

   …Restated Certificate of Incorporation with the Secretary of State of Delaware to effect a 1-for-50 reverse stock split of the outstanding shares of our common stock. The Company’s stockholders previously approved the Reverse Stock Split at our annual meeting of stockholders held on July 25, 2025. The Reverse Stock Split became effective after market on August 11, 2025 with the Company’s Common Stock trading on the OTCQB on a split-adjusted…
6. QNCXQuince Therapeutics, Inc.424B5Nueva emisión de acciones con precioEDGAR
7. VBIOValion Bio, Inc.S-3Capacidad de emisión registradaEDGAR
   En el documentoDuda sustancial sobre la continuidad de la empresatexto original ▸

   …Company’s financial statements at December 31, 2024 and 2023, and for the years then ended, as set forth in their report thereon (which contains an explanatory paragraph describing conditions that raise substantial doubt about the Company’s ability to continue as a going concern), which is incorporated herein by reference. Such financial statements are incorporated herein by reference in reliance on Rosenberg Rich Baker Berman, P.A.’s report, given on the authority of such firm…

   En el documentoContrasplit de accionestexto original ▸

   …registered hereunder. As of October 15, 2025, all 1,750 of the Fourth Tranche Preferred Shares remain outstanding. Reverse Stock Splits Reverse Stock Split - 2025 Effective March 7, 2025, the Company implemented a reverse stock split of the Company’s issued and outstanding shares of common stock at a ratio of 1-for-17. As a result of the reverse stock split, the total number of shares of common stock held by each stockholder of the…
8. MAZEMaze Therapeutics, Inc.S-1Capacidad de emisión registradaEDGAR
9. MDCXMedicus Pharma Ltd.424B3Prospecto suplementario o de reventaEDGAR
10. MDCXMedicus Pharma Ltd.424B3Prospecto suplementario o de reventaEDGAR
11. MDCXMedicus Pharma Ltd.424B3Prospecto suplementario o de reventaEDGAR

Participaciones y control

1. ARTLARTELO BIOSCIENCES, INC.SC 13D/ACambio en participación significativaEDGAR
2. HRTXHERON THERAPEUTICS, INC. /DE/SC 13D/ACambio en participación significativaEDGAR
3. SYRESpyre Therapeutics, Inc.SC 13D/ACambio en participación significativaEDGAR
4. VORVor Biopharma Inc.SC 13D/ACambio en participación significativaEDGAR

Informes y hechos relevantes

1. ASBPAspire-Lakewood Holdings, Inc.8-KAviso de incumplimiento de cotizaciónEDGAR
2. GNPXGenprex, Inc.8-KAviso de incumplimiento de cotizaciónEDGAR
   En el documentoContrasplit de accionestexto original ▸

   …discretion to effect the Reverse Stock Split at a ratio of not less than one-for-ten (1:10) and not more than one-for-fifty (1:50), with such ratio to be determined by the Board. On October 1, 2025, the Board approved a Reverse Stock Split ratio of one-for-fifty (1:50) and authorized the filing of the Certificate of Amendment. The foregoing description of the Certificate of Amendment is a summary of the material terms thereof, does not…

   En el documentoDesignación de medicamento huérfanotexto original ▸

   …first half of 2026 and expects the interim analysis in the second half of 2026. The Acclaim-3 clinical trial has received FDA Fast Track Designation for this patient population and Acclaim-3 has also received an FDA Orphan Drug Designation. The Company has initiated the addition of new clinical trial sites for both Acclaim-1 and Acclaim-3, and Genprex expects to open additional sites by the end of 2025. The Company believes the addition…
3. LXEOLexeo Therapeutics, Inc.8-KVenta de acciones no registrada (colocación privada)EDGAR
4. MDCXMedicus Pharma Ltd.8-KVenta de acciones no registrada (colocación privada)EDGAR
5. RANIRani Therapeutics Holdings, Inc.8-KVenta de acciones no registrada (colocación privada)EDGAR
6. SCNXScienture Holdings, Inc.8-KAviso de incumplimiento de cotizaciónEDGAR
7. SRZNSurrozen, Inc./DE8-KFin de acuerdo materialEDGAR
8. ARTLARTELO BIOSCIENCES, INC.8-KNuevo acuerdo materialEDGAR
9. CLNNClene Inc.8-KOtros hechos relevantesEDGAR
10. CLYMClimb Bio, Inc.8-KOtros hechos relevantesEDGAR
11. IRONDisc Medicine, Inc.8-KOtros hechos relevantesEDGAR
12. PRLDPrelude Therapeutics Inc8-KCambio en el consejo o la direcciónEDGAR
13. PROKPROKIDNEY CORP.8-KNuevo acuerdo materialEDGAR
14. RKTORocket One Inc.8-KOtros hechos relevantesEDGAR
15. RNAZTranscode Therapeutics, Inc.8-K/ANuevo acuerdo materialEDGAR
16. RVMDRevolution Medicines, Inc.8-KOtros hechos relevantesEDGAR
17. SPRBSPRUCE BIOSCIENCES, INC.8-KCambio en el consejo o la direcciónEDGAR
18. TRAWTraws Pharma, Inc.8-KCambio en el consejo o la direcciónEDGAR
19. XENEXenon Pharmaceuticals Inc.8-K/ACambio en el consejo o la direcciónEDGAR
    En el documentoCambio en la dirección de la empresatexto original ▸

    …Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On October 16, 2025, Xenon Pharmaceuticals Inc. (the “Company”) announced that Thomas (Tucker) Kelly has been appointed to serve as the Company’s Chief Financial Officer, effective October 15, 2025. In connection with his appointment, Mr. Kelly will serve as the Company’s principal financial officer and principal accounting officer. Mr. Kelly, age 54, previously served…

← jueves 16 de octubre de 2025 · lunes 20 de octubre de 2025 →

Esto mismo, cada mañana y solo de tus empresas. Sigue a las que te interesen y recibe en tu correo lo que presenten ante la SEC, en castellano. Crear una cuenta. ¿Ya tienes cuenta? Entrar.

Esto no son recomendaciones de inversión. Son hechos públicos verificables en su fuente. Lee siempre el documento original antes de decidir nada. Aviso legal.